Three things to know:
1. The orthopedic implant manufacturer recently received FDA-approval to launch an investigation device exemption clinical study in the U.S. to evaluate its BioPoly RS Partial Resurfacing Knee implant.
2. The BioPoly material is designed to function like an artificial cartilage because of its patented combination of a molecule found in cartilage with a polyethylene-based plastic. The material is intended to replace the damaged cartilage rather than the entire joint.
3. Since 2012, patients in Europe have received the implants.
More articles on devices:
Shift to outpatient setting drives global orthopedic implants market — 5 insights
Xtant Medical names new COO: 4 things to know
Spinal fusion devices make up 58% of products market — 10 key players
